Related Experiment Video

Updated: Apr 13, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer

Teresa C Longoria, Ramez N Eskander1

  • 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine-Medical Center, 101 The City Drive, Bldg 56, Ste 800, ZC 3200, Orange, CA 92868 USA. Eskander@uci.edu.

Recent Patents on Anti-Cancer Drug Discovery
|May 5, 2015
PubMed

Insights

Innovative immunotherapies targeting immune checkpoints are crucial for improving ovarian cancer survival rates. This review explores anti-CTLA-4 and anti-PD1 antibodies for advanced ovarian cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Ovarian cancer is the leading cause of gynecologic cancer deaths, with stagnant mortality rates over 40 years.
  • Immune checkpoints are regulatory pathways that suppress immune responses, often exploited by cancer cells.
  • Novel immunotherapeutic strategies are needed to overcome immune evasion in advanced ovarian cancer.

Purpose of the Study:

  • To review the development and application of immune checkpoint inhibitors in ovarian cancer.
  • To discuss the role of anti-CTLA-4 and anti-PD1 monoclonal antibodies in treating advanced epithelial ovarian cancer (EOC).
  • To examine recent patents involving immune checkpoint inhibition for cancer treatment.

Main Methods:

  • Review of scientific literature on immune checkpoint inhibitors.
  • Analysis of clinical trial data for anti-CTLA-4 and anti-PD1 antibodies in EOC.
  • Survey of recent patent filings related to cancer immunotherapy.

Main Results:

  • Anti-CTLA-4 and anti-PD1 antibodies represent a promising immunotherapeutic approach for EOC.
  • Ongoing research and clinical trials are expanding the use of these inhibitors.
  • Patents indicate continued innovation in harnessing immune checkpoints for cancer therapy.

Conclusions:

  • Immune checkpoint inhibitors offer a vital new avenue for treating advanced ovarian cancer.
  • Further research and clinical application of these therapies are essential.
  • The field is rapidly evolving, with significant patent activity highlighting future directions.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K